Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU Ups The Ante On Opposition To COVID-19 IP Waiver

Executive Summary

Leaked documents show that the European Commission has prepared a new proposal on compulsory licensing of coronavirus products to be tabled at the World Trade Organization’s Ministerial Conference next month.

You may also be interested in...



More Pressure On COVID-19 Product Protections As Euro Parliament Backs IP Waiver

Expectations will be high after the COVID-19 product IP waiver plan took a big step forward and G7 leaders prepare for discussions on the global recovery from coronavirus, tackling climate change and other weighty subjects.

EU Still Resisting COVID-19 Vaccine IP Waiver

The pharmaceutical industry and Médecins Sans Frontières have both criticized the EU’s proposals for avoiding a waiver of intellectual property rights on COVID-19 vaccines and treatments, albeit for different reasons.

EU Backs Compulsory Licensing & Production Boost For COVID-19 Vaccines

The European Commission is to present the World Health Organization with a set of proposals to tackle the barriers to the global rollout of COVID-19 vaccines. They include allowing the issue of compulsory licenses without consulting the rights holder, encouraging vaccine companies to expand production through licensing deals and contract manufacturing, and eliminating vaccine export restrictions.

Topics

UsernamePublicRestriction

Register

PS145104

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel